Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients

Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)

These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin

Inclusion Criteria:

• Informed consent
• de novo or secondary LAM (CML excluded) not elligible for intensive chemotherapy.
• Previously untreated

Exclusion Criteria:

• Renal impairment (serum creatinin >2N)

• Hepatic impairment (TGO ou TGP > 5N), une cholestase (Phosphatases Alcalines or gamma-GT > 5N),bilirubin > 3N

  • Blast crisis CML
  • Acute Promyelocytic Leukemia.